Michael Gwarisa
United States President Donald Trump signed into law a US$5.88 billion bipartisan spending package on February 3, 2026 that restores and expands American support for global HIV initiatives, according to a statement from the Joint United Nations Programme on HIV/AIDS (UNAIDS).
The package represents one of the largest single‑year pledges of U.S. government funding for the global HIV response in recent years and comes amid broader debates over foreign aid priorities and public health spending.
The consolidated spending bill earmarks US$4.6 billion for bilateral HIV programmes through the United States’ America First Global Health Strategy, US$1.25 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria, and US$45 million for UNAIDS. These investments are intended to support prevention, treatment and care services in partner countries around the world.
UNAIDS described the funding as a strong demonstration of U.S. leadership. “I thank President Trump and the U.S. Congress for their continued commitment to HIV and global health,” said Winnie Byanyima, Executive Director of UNAIDS, in a press release.
“This U.S. investment will provide life‑saving support for millions of people in partner countries and help to ensure that the global HIV response remains efficient, data‑driven and delivers results.”
Why This Funding Is Important
U.S. global funding for HIV is a cornerstone of the international response to the epidemic. The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), launched in 2003, is the largest commitment by any nation to combat a single disease, with total contributions exceeding US$100 billion since its inception. It has helped save over 25 million lives and supported HIV treatment and prevention programmes across more than 50 countries.
Despite this long track record of impact, funding levels have fluctuated, particularly in recent years. In the fiscal year (FY) 2025, global HIV funding was approximately US$6.5 billion, including bilateral programmes and contributions to multilateral partners such as the Global Fund and UNAIDS. However, proposed U.S. budget cuts and a partial foreign aid freeze announced by the administration in 2025 raised concerns among global health experts about disruptions to HIV services and progress toward ending the epidemic.
The 2026 funding package is therefore seen as important for stabilising and strengthening programmes that had been at risk of scale‑backs, and for reaffirming long‑standing bipartisan support in Congress for investments in global HIV response.
Global Targets and Strategy
The funding aligns with international goals to end AIDS as a public health threat by 2030. UNAIDS and other global partners promote the 95‑95‑95 targets, which aim for 95 percent of people living with HIV to know their status, 95 percent of those diagnosed to be on sustained antiretroviral therapy, and 95 percent of those on therapy to achieve viral suppression. The U.S. contribution is expected to help advance these targets by supporting testing, treatment access and data‑driven strategies in countries most affected by HIV.
Following the funding cuts in 2025, many global HIV advocates warned that cuts or pauses in U.S. funding could disrupt treatment supply chains, community‑based services and prevention efforts.
In Zimbabwe, health authorities have warned that new HIV infections, especially among young adolescent girls and women, have been on an upward trend in most high HIV burden districts.
In Matabeleland South, all seven districts show prevalence rates significantly above the national average of 9.8%, underlining a persistent HIV pattern.
